[VIRTUAL] FORTITUDE phase I study of NG-350A, a novel tumour-selective adenoviral vector expressing an anti-CD40 agonist antibody: Monotherapy dose escalation results

NG-350A - PsiOxus

A. Naing1; L. Rosen2; R.D. Camidge3; D. Khalil4; J. Davies5; D. Miles5; M. Patel6; P. Cockle7; B. Champion7; D. Krige5; T. Lillie5

Jul 22, 2021